# A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting

> **NCT05389709** · — · COMPLETED · sponsor: **Bayer** · enrollment: 184 (actual)

## Conditions studied

- Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia
- Irritable Bowel Syndrome
- Functional Dyspepsia

## Interventions

- **DRUG:** Iberogast (STW5-II, BAY98-7410)

## Key facts

- **NCT ID:** NCT05389709
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-04
- **Primary completion:** 2023-05-11
- **Final completion:** 2023-05-11
- **Target enrollment:** 184 (ACTUAL)
- **Last updated:** 2023-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05389709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05389709, "A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05389709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*